

Curriculum Vitae Sam S. Dahr, M.D.

Physical and Mailing Addresses

Retina Center of Oklahoma
3366 Expressway, Suite 670
Oklahoma City, Oklahoma 73112
Telephone (405) 713-4410 (office)
(405) 748-0040 (cell)
Fax (405) 713-4409
sam@rcoklahoma.com

Biographical Information

Born: Oklahoma City, Oklahoma.

Current Positions

Vitreoretinal surgeon and founder, Retina Center of Oklahoma (2006-present)

Primary retinal consultant to the Division of Ophthalmic and ENT Devices, U.S. Food and Drug Administration (2007-present)

Standing Member, Medical Device Advisory Committee, Ophthalmic Devices Panel, U.S. Food and Drug Administration (2017-present)

Clinical Associate Professor, University of Oklahoma College of Medicine, Department of Ophthalmology and the Dean McGee Eye Institute (2016-present)

Chairman, Department of Ophthalmology, Integris Baptist Medical Center (2013-present)

President-elect, Oklahoma County Medical Society (2017-present)

Board of Directors, Oklahoma State Medical Association (2014-present)

Writing Committee, American Academy of Ophthalmology Basic and Clinical Science Course, Section 9, Intraocular Inflammation and Uveitis (2016-present)

Education and Training

Undergraduate &
Graduate

September 1991-
June 1995

Stanford University, Stanford California,
B.S. Biological Sciences,
M.S. Management Science/Engineering-Economic Systems

Medical Doctorate

August 1995-
June 1999

University of Oklahoma College of Medicine
Oklahoma City, Oklahoma
M.D.

Internship

July 1999-
June 2000

Department of Internal Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Residency

July 2000-
July 2003

University of Cincinnati Medical Center
Cincinnati, Ohio,
Resident Physician and Surgeon, Department of Ophthalmology

Fellowships

July 2003
-June 2005

National Eye Institute, National Institutes of Health
Bethesda, Maryland,
Clinical Fellow, Medical Retina

July 2003

-June 2005

National Eye Institute, National Institutes of Health
Bethesda, Maryland,
Clinical Fellow, Uveitis and Ocular Immunology

July 2005

-July 2006

University of Cincinnati and the Cincinnati Eye Institute
Cincinnati, Ohio
Surgical Fellow, Vitreoretinal Surgery and Ocular Oncology

Professional Experience

July 2003-

June 2005

Senior Staff Fellow, Magnuson Clinical Center, National Eye Institute, National Institutes of Health
Bethesda, Maryland

July 2005-

July 2006

Instructor, Retina and Uveitis, Department of Ophthalmology, University of Cincinnati College of Medicine

August 2006

-present

Retina Center of Oklahoma, Oklahoma City, Oklahoma

March 2007-

October 2011;

April 2014-present

Specialized Experts Program (SGE), U.S. Food and Drug Administration (FDA), Office of Device Evaluation (ODE). Service as primary retinal consultant to the Division of Ophthalmic and ENT Devices (DOED)

November 2011-

March 2014

FDA Medical Device Fellow, with continued service as primary retinal consultant to the Division of Ophthalmic and ENT Devices (DOED)

January 2013-

present

Chairman, Department of Ophthalmology, Integris Baptist Medical Center, Oklahoma City, Oklahoma

August 2016-

present

Clinical Associate Professor, University of Oklahoma College of Medicine and the Dean McGee Eye Institute, Oklahoma City, Oklahoma

January 2017-

present

Standing Member, Medical Device Advisory Committee, Ophthalmic Devices Panel, U.S. Food and Drug Administration

FDA Panels

Evaluation of the Second Sight Argus II Retinal Prosthesis System. Role: FDA consulting medical officer presenting safety data to the panel. FDA Ophthalmic Devices Advisory Panel, Gaithersburg, Maryland, September 28, 2014.

Evaluation of the AcuFocus Kamra inlay. Role: Temporary voting member. FDA Ophthalmic Devices Advisory Panel, Gaithersburg, Maryland, June 6, 2014.

**FDA Panels
(continued)**

Risks of misuse of peroxide based contact lens products. Role: Standing voting member. FDA Ophthalmic Devices Advisory Panel, Gaithersburg, Maryland, March 17, 2017.

Leadership

2007-present

Vice-Chair, Continuing Medical Education (CME) Committee, Integris Baptist Medical Center, Oklahoma City, Oklahoma

2012-2013

Oklahoma County Medical Society Leadership Academy

January 2013-present

Chairman, Department of Ophthalmology, Integris Baptist Medical Center, Oklahoma City, Oklahoma

January 2014-present

Board of Directors, Oklahoma State Medical Association

January 2014-present

Board of Directors, Oklahoma County Medical Society

January 2016-December 2016

Vice President, Oklahoma County Medical Society

Honors and Awards

Boothe Prize for Excellence in Writing Finalist, Stanford University, 1996.

University of Oklahoma College of Medicine Excellence in Research Award: A Bayesian Approach to the Prospective Evaluation of Clinical Trials, November 1996.

Certificate of Appreciation, U.S. Food and Drug Administration, July 2010 (presented for three years of work as the primary retinal consultant to the Ophthalmic Device Division).

Letter of Commendation, U.S. Food and Drug Administration, September 2013 (presented for outstanding public service in the premarket regulatory review of novel retinal medical and surgical devices)

Boards and Licensure

USMLE Step 1, No. 5-026-874-7, June 1997.
USMLE Step 2, No. 5-026-874-7, August 1998.
USMLE Step 3, No. 5-026-874-7, June 2000.
Permanent License, Oklahoma, No. 21812 (10/04/2000-current).
Diplomate, American Board of Ophthalmology, June 2005. Successful
Recertification/MOC to June 2025.

Professional Societies

American Academy of Ophthalmology
Association for Research in Vision and Ophthalmology
International Ocular Inflammation Society
American Society of Retina Specialists
American Uveitis Society
Oklahoma County Medical Society
Oklahoma State Medical Association

Publications

Dahr, S. S., Cusick, M., Rodriguez-Coleman, H., Srivastava, S. K.,
Thompson, D. J., Linehan, W. M. et al. (2007). Intravitreal anti-
vascular endothelial growth factor therapy with pegaptanib for
advanced von hippel-lindau disease of the retina. *Retina*, 27(2), 150-
158.

McCulley, T. J., Mayer, K., Dahr, S. S., Simpson, J., & Holland, E. J.
(2005). Aniridia and optic nerve hypoplasia. *Eye (Lond)*, 19(7), 762-
764.

Meyerle, C. B., Dahr, S. S., Wetjen, N. M., Jirawuthiworavong, G. V.,
Butman, J. A., Lonser, R. R. et al. (2008). Clinical course of
retrobulbar hemangioblastomas in von hippel-lindau disease.
Ophthalmology, 115(8), 1382-1389.

Nussenblatt, R. B., Coleman, H., Jirawuthiworavong, G., Davuluri, G.,
Potapova, N., Dahr, S. S. et al. (2007). The treatment of multifocal
choroiditis associated choroidal neovascularization with sirolimus
(rapamycin). *Acta Ophthalmol Scand*, 85(2), 230-231.

Wallace, D. J., Shen, D., Reed, G. F., Miyanaga, M., Mochizuki, M., Sen,
H. N., Dahr, S. S. et al. (2006). Detection of the bcl-2 t(14;18)
translocation and proto-oncogene expression in primary intraocular
lymphoma. *Invest Ophthalmol Vis Sci*, 47(7), 2750-2756.

Yeh, S., Wroblewski, K., Buggage, R., Li, Z., Kurup, S. K., Sen, H. N., Dahr, S.S. et al. (2008). High-dose humanized anti-il-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. *Journal of Autoimmunity*, 31(2), 91-97.

Book chapters

S.S. Dahr, K.C. Csaky. Vascular Endothelial Growth Factor (VEGF) and Retinal Diseases. *Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics*. Joyce Tombran-Tink and Colin Barnstable, editors. Humana Press, 2006.

S.S. Dahr. Local Therapy for Uveitis. *Wills Eye Color Atlas and Synopsis: Uveitis*. Robert Nussenblatt and H. Nida Sen, editors. Lippincott, 2011.

Abstracts

S.S. Dahr, D.M. Miller, C.D. Riemann, R.E. Foster, M.R. Petersen. Endophthalmitis associated with 25 gauge vitrectomy. AAO 2006.

S.S. Dahr, H. Coleman, C.C. Chan, E.Y. Chew, K.G. Csaky. Reduction in IOP Elevation After Excision of Anterior SubTenon Triamcinolone Depot. AAO 2005.

H. Coleman, S.S. Dahr, E.Y. Chew. High-Dose Systemic Steroids May Improve Visual Prognosis in VHL Patients Undergoing Cryotherapy for Hemangioblastomas. AAO 2005.

G.V. Jirawuthiworavong, S.S. Dahr, N.M. Wetjen, R.R. Lonser, E. Oldfield, J.A. Butman, H. Coleman, and E.Y. Chew. Clinical Course of Rare Supratentorial Hemangioblastomas in von-Hippel Lindau Disease That Affect the Afferent Visual Pathway From the Retrobulbar Optic Nerve to the Optic Chiasm. *Invest. Ophthalmol. Vis. Sci.* 2006 47: E-Abstract 4709.

S.S. Dahr, J. Rosenthal, W. Gilmer, H. Coleman, K. Csaky, M. Robinson, E. Agron, and E.Y. Chew. Anterior Subtenon's Triamcinolone Acetonide (ASTA) Injection for the Treatment of Diabetic Macular Edema: 4 to 6 Month Clinical Followup. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1431.

K.G. Csaky, H. Coleman, S. Dahr, E. Chew, J. Rosenthal, W. Gilmer, H. Kim, P. Yuan, S. Cousins, and M. Robinson. Anterior Subtenon's Triamcinolone Acetonide (ASTTA) Injection for the Treatment of Diabetic Macular Edema: Animal and Clinical Findings. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 4670.

D.J. Wallace, D. Shen, G.F. Reed, M. Mochizuki, H.N. Sen, S.S. Dahr, R.R. Buggage, R.B. Nussenblatt, and C.C. Chan
The Role of the bcl-2 t(14;18) Translocation in Clinical Outcomes of Primary Intraocular Lymphoma. Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 3465.

S.S. Dahr, S. Srivastava, E.Y. Chew. Retrobulbar optic nerve hemangioblastomas associated with Von Hippel-Lindau Syndrome (VHL). AAO 2004.

S.K. Kurup, R. Ursea, J. Tang, W.-K. Lim, H.N. Sen, S. Dahr, R.R. Buggage, and R.B. Nussenblatt. Utility of a Gamma Interferon assay as an alternative to PPD TB skin testing in selected patients with intraocular inflammatory disease. Invest. Ophthalmol. Vis. Sci. 2004 45: E-Abstract 1678.

M. Cusick, S.S. Dahr, S. Srivastava, H.R. Coleman, D. Thompson, and E.Y. Chew. Intravitreal Anti-VEGF Therapy for Advanced Ocular Disease of Von Hippel-Lindau Disease. Invest. Ophthalmol. Vis. Sci. 2004 45: E-Abstract 1184.

S.S. Dahr, T.J. McCulley, R.C. Kersten, S.S. Schneider, and R.K. Hutchins. Decision Factors for Primary Enucleation in a Trauma Setting: A Clinicopathologic Study. Invest. Ophthalmol. Vis. Sci. 2003 44: E-Abstract 822.

S.S. Dahr, T.J. McCulley, B.L. Lam, and W.J. Feuer. The Effect of Optic Disk Edema On Spontaneous Venous Pulsations In The Absence Of Elevated Intracranial Pressure. Invest. Ophthalmol. Vis. Sci. 2002 43: E-Abstract 244.

Presentations at major conferences

"Punctate inner choroidopathy: correlation of scanner laser ophthalmoscopy and ICG angiography." American Uveitis Society meeting, Anaheim, California, November 15, 2003.

"Sclerokeratitis associated with Cogan's syndrome." Tenth Annual Foster Ocular Immunology Society Meeting, Ft. Lauderdale, Florida, May 1, 2005.

"Toxoplasma retinochoroiditis associated with atovaquone resistance." Poster presentation, International Ocular Inflammation Society, Paris, France, September 18, 2007.

“Bilateral endogenous *Histoplasma* endophthalmitis simulating serpiginous choroiditis.” Case presentation, International Ocular Inflammation Society, Prague, Czech Republic, May 31, 2009.

“Bilateral endogenous *Histoplasma* endophthalmitis simulating serpiginous choroiditis.” Poster presentation, Retina Congress, New York City, New York, October 2, 2009.

“A cryptic diagnosis: chronic bilateral intermediate uveitis and macular edema secondary to Rocky Mountain Spotted Fever, with complete resolution after doxycycline monotherapy.” Case presentation, World Ophthalmology Congress, Abu Dhabi, United Arab Emirates, February 18, 2012.

“Hospitalized patients with endogenous MRSA endophthalmitis and unable to undergo vitrectomy may achieve good outcomes with bedside intravitreal antibiotic injection alone.” Poster presentation, World Ophthalmology Congress, Abu Dhabi, United Arab Emirates, February 18, 2012.

“Nongranulomatous anterior and intermediate uveitis secondary to selective BRAF mutation inhibitor treatment for metastatic cutaneous melanoma: a case series.” Poster presentation, World Ophthalmology Congress, Tokyo, Japan, April 5, 2014. Co-authors: S.R. Amin, M. Page, R. Beardsley, R. Vile, and J. Pulido of the Mayo Clinic.

“Reversible OCT findings associated with retinopathy secondary to Dengue fever infection.” Poster presentation, World Ophthalmology Congress, Tokyo, Japan, April 5, 2014.

“Traditional steroid sparing therapy for noninfectious uveitis.” Instructional course, American Society of Retina Specialists Annual Meeting, San Diego, California, August 12, 2014

“FDA Regulation of Ophthalmic Medical devices.” Annual Meeting of the Retina Society, Paris, France, October 8, 2015.

“Traditional steroid sparing therapy for noninfectious uveitis.” Instructional course, American Society of Retina Specialists Annual Meeting, San Francisco, California, August 9, 2016

Invited Lectures

"Principles of uveitis evaluation and therapy." Kresge Eye Institute, Detroit, Michigan, September 22, 2004.

“Steroid-sparing therapy for uveitis.” Department of Ophthalmology 20th Annual Ophthalmology Conference and Research Symposium, University of Cincinnati, Cincinnati, Ohio, April 10, 2015. Keynote invited speaker.

“The FDA and Ophthalmology.” Department of Ophthalmology 20th Annual Ophthalmology Conference and Research Symposium, University of Cincinnati, Cincinnati, Ohio, April 10, 2015. Keynote invited speaker.

Educational Lectures

“Evolving Therapies in Posterior Uveitis.” Midwest Ophthalmology Conference, Cincinnati, Ohio, September 17, 2005.

“Age Related Eye Diseases,” Women’s Health Forum, Oklahoma City, Oklahoma, September 14, 2007.

“Retinal Detachment Surgery.” Oklahoma Academy of Optometric Physicians Annual Educational Meeting, Tulsa, Oklahoma, October 13, 2007.

“Retinovascular Eye Disease.” Oklahoma Academy of Optometric Physicians Annual Educational Meeting, Tulsa, Oklahoma, October 13, 2007.

“Diabetic Eye Disease.” Integris Southwest Hospital Grand Rounds, Oklahoma City, Oklahoma, November 14, 2007.

“Macular Degeneration.” Mercy Hospital Grand Rounds, Oklahoma City, Oklahoma, February 7, 2008.

“Diabetic Eye Disease Mercy Hospital Grand Rounds, Oklahoma City, Oklahoma, February 21, 2008.

“Macular hole associated with *Bartonella* neuroretinitis.” National Institutes of Health, National Eye Institute, Laboratory of Immunology Alumni Day, Bethesda, Maryland, June 13, 2008.

“Diabetic Eye Disease.” Integris Baptist Hospital Grand Rounds, Oklahoma City, Oklahoma, September 4, 2008.

“Adult Intraocular Tumors.” Oklahoma Academy of Optometric Physicians Regional Educational Meeting, Oklahoma City, Oklahoma, April 4, 2009.

“Retinal Detachment Surgery.” Mercy Hospital Grand Rounds, Oklahoma City, Oklahoma, April 23, 2009.

“Uveitis Principles and Practice.” Department of Rheumatology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, June 17, 2009.

“Mystery Uveitis Case,” Dean McGee Eye Institute Research Day, Oklahoma City, Oklahoma, June 20, 2009.

“Art of Macula I: pseudophakic cystoid macular edema, macular pucker, and vitreomacular traction syndromes.” Oklahoma Academy of Optometric Physicians Regional Educational Meeting, Oklahoma City, Oklahoma, March 26, 2010.

“A strange case of anterior uveitis: or is it?” Atlantic Coast Retina Conference, Philadelphia, Pennsylvania, January 10, 2014.

“Masquerades in ophthalmology.” Dean McGee Eye Institute Research Day, Oklahoma City, Oklahoma, June 14, 2014.

“Reversible OCT findings associated with retinopathy secondary to Dengue fever infection.” Mayo Clinic Retina Update and Conference, Rochester, Minnesota, October 31, 2014.

“Retinal manifestations of systemic disease.” Integris Baptist Hospital Grand Rounds, Oklahoma City, Oklahoma, November 3, 2014.

Other recognition

“Reporter Gets Firsthand Glimpse at Retinal Trauma,” Sonya Colberg, The Sunday Oklahoman, May 23, 2010. <http://newsok.com/retinal-tear-gives-oklahoman-reporter-firsthand-look-at-eye-trauma/article/3463226>